Atrion Co. (NASDAQ:ATRI) Stock Holdings Increased by Kayne Anderson Rudnick Investment Management LLC

Kayne Anderson Rudnick Investment Management LLC boosted its stake in shares of Atrion Co. (NASDAQ:ATRI) by 1.0% during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 205,393 shares of the medical instruments supplier’s stock after purchasing an additional 2,111 shares during the period. Kayne Anderson Rudnick Investment Management LLC owned about 0.12% of Atrion worth $92,926,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in ATRI. Vanguard Group Inc. boosted its stake in shares of Atrion by 0.4% during the 1st quarter. Vanguard Group Inc. now owns 84,876 shares of the medical instruments supplier’s stock valued at $39,344,000 after buying an additional 326 shares during the period. Bank of New York Mellon Corp raised its holdings in shares of Atrion by 3.0% during the second quarter. Bank of New York Mellon Corp now owns 14,921 shares of the medical instruments supplier’s stock worth $6,751,000 after acquiring an additional 436 shares in the last quarter. Versor Investments LP purchased a new stake in shares of Atrion during the second quarter worth $3,247,000. Penn Mutual Asset Management LLC acquired a new stake in Atrion during the fourth quarter valued at $1,949,000. Finally, Envestnet Asset Management Inc. grew its stake in Atrion by 27.1% in the second quarter. Envestnet Asset Management Inc. now owns 4,986 shares of the medical instruments supplier’s stock valued at $2,256,000 after purchasing an additional 1,063 shares in the last quarter. Institutional investors and hedge funds own 66.19% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, StockNews.com assumed coverage on Atrion in a report on Thursday. They set a “sell” rating for the company.

Atrion Price Performance

NASDAQ ATRI opened at $459.92 on Friday. The company has a 50 day moving average price of $458.99 and a two-hundred day moving average price of $445.26. Atrion Co. has a 12-month low of $274.98 and a 12-month high of $503.24. The stock has a market capitalization of $809.46 million, a PE ratio of 43.23 and a beta of 0.69.

Atrion (NASDAQ:ATRI) last issued its quarterly earnings data on Thursday, August 8th. The medical instruments supplier reported $0.23 earnings per share (EPS) for the quarter. The firm had revenue of $48.77 million during the quarter. Atrion had a net margin of 10.60% and a return on equity of 7.75%.

Atrion Profile

Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.